Need professional-grade analysis? Visit stockanalysis.com
$3.37B
N/A
92
N/A
Dianthus Therapeutics Inc. (DNTH) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $91.29, up 1.26% from the previous close.
Over the past year, DNTH has traded between a low of $16.86 and a high of $95.76. The stock has gained 330.0% over this period. It is currently 441.6% above its 52-week low.
Dianthus Therapeutics Inc. has a market capitalization of $3.37B.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Side-by-side comparison against top Healthcare peers.